title: MMP-2 and DcR3 expression in esophageal cancer tissue and correlation with patient survival.
abstract: OBJECTIVE
  This study aims to explore the expression of decoy receptor 3 (DcR3) and the matrix metalloproteinase-2 (MMP-2) in esophageal carcinoma and their relationship with patient survival.
  
  
  METHODS
  The EnVision(TM) immunohistochemistry method was used to examine DcR3 and MMP-2 expression in 150 surgical biopsies of esophageal carcinoma. Expression level was compared with clinical indices and with patient survival.
  
  
  RESULTS
  In cancer tissues, the positive expression rate of DcR3 and MMP-2 was 54.00% and 54.67% respectively; this was higher than levels in adjacent normal tissue. DcR3 and MMP-2 were positively correlated with carcinoma size, lymphatic metastasis, invasion degree, clinical stage and 3-year survival. DcR3 and MMP-2 were not correlated with gender, age and tumor degree of differentiation. DcR3 and MMP-2 were positively correlated between in the two groups (r = 0.37, P < 0.01). Kaplan-Meier survival curve showed that higher rates of DcR3 and MMP-2 expression correlated with lower survival.
  
  
  CONCLUSIONS
  Determining DcR3 and MMP-2 expression may be useful for the diagnosis, treatment and prognosis of patients with esophageal carcinoma.
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital of China Medical University Shenyang, China.
authors.forename: Ran
authors.initials: R
authors.lastname: Ao
authors.forename: Ya-Qi
authors.initials: YQ
authors.lastname: Du
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Yu-Shuai
authors.initials: YS
authors.lastname: Chen
authors.forename: Bing-Yuan
authors.initials: BY
authors.lastname: Wang
keywords: Esophageal cancer; decoy receptor; matrix metalloproteinase-2
references.citation: Neoplasia. 2008 Oct;10(10):1049-56
references.pmid: 18813347
references.citation: Gynecol Oncol. 2008 Nov;111(2):330-5
references.pmid: 18723214
references.citation: Cell Mol Immunol. 2007 Dec;4(6):455-60
references.pmid: 18163957
references.citation: Cancer Invest. 2008 Dec;26(10):965-74
references.pmid: 19093253
references.citation: J Clin Pathol. 2006 Jun;59(6):618-23
references.pmid: 16731602
references.citation: Arthritis Rheum. 2007 Apr;56(4):1067-75
references.pmid: 17393415
references.citation: J Immunol. 2005 Feb 1;174(3):1647-56
references.pmid: 15661928
references.citation: Br J Cancer. 2005 Sep 5;93(5):544-51
references.pmid: 16091761
references.citation: Carcinogenesis. 2010 Jan;31(1):9-18
references.pmid: 19887512
references.citation: Biochemistry. 2009 Aug 18;48(32):7636-45
references.pmid: 19522538
references.citation: J Immunol. 2005 Oct 15;175(8):5135-45
references.pmid: 16210617
references.citation: Cancer. 2003 May 15;97(10):2412-9
references.pmid: 12733139
references.citation: Anticancer Res. 2007 Sep-Oct;27(5B):3593-600
references.pmid: 17972522
references.citation: J Immunol Methods. 2004 Feb 1;285(1):63-70
references.pmid: 14871535
references.citation: J Cancer Res Clin Oncol. 2004 Jan;130(1):37-44
references.pmid: 14569466
references.citation: Cancer Res. 2004 Feb 1;64(3):1122-9
references.pmid: 14871847